Experienced in Pseudobulbar Affect

Francois Salachas

Centre De Référence Maladies Neuromusculaires Paris Est, 
Paris, FR 
Experienced in Pseudobulbar Affect
Centre De Référence Maladies Neuromusculaires Paris Est, 
Paris, FR 
OverviewLocationsClinical Research

Overview

Francois Salachas practices in Paris, France. Mr. Salachas is rated as an Experienced expert by MediFind in the treatment of Pseudobulbar Affect. His top areas of expertise are Primary Lateral Sclerosis, Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), Spinal Muscular Atrophy (SMA), Riboflavin Transporter Deficiency Neuronopathy, and Gastrostomy.

His clinical research consists of co-authoring 95 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Pseudobulbar Affect.

Gender
Male

Locations

Centre De Référence Maladies Neuromusculaires Paris Est, Paris, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Clinical and Genetic Study of Neurodegenerative Disorders With Cognitive Impairment
Clinical and Genetic Study of Neurodegenerative Disorders With Cognitive Impairment
Enrollment Status: Completed
Publish Date: January 23, 2025
Intervention Type: Other
Efficacy and Safety of Low-dose IL-2 (Ld-IL-2) as a Treg Enhancer for Controlling Neuro-inflammation in Newly Diagnosed Amyotrophic Lateral Sclerosis (ALS) Patients: A Randomized, Double-blind, Placebo- Controlled, Phase-II Proof of Concept/ Proof of Mechanism Clinical Trial
Efficacy and Safety of Low-dose IL-2 (Ld-IL-2) as a Treg Enhancer for Controlling Neuro-inflammation in Newly Diagnosed Amyotrophic Lateral Sclerosis (ALS) Patients: A Randomized, Double-blind, Placebo- Controlled, Phase-II Proof of Concept/ Proof of Mechanism Clinical Trial
Enrollment Status: Completed
Publish Date: April 11, 2022
Intervention Type: Drug
Study Drugs: Riluzole, IL-2
Study Phase: Phase 2
Evaluation of Metabolomic Analysis in Early Diagnosis of ALS
Evaluation of Metabolomic Analysis in Early Diagnosis of ALS
Enrollment Status: Completed
Publish Date: July 17, 2019
Intervention Type: Procedure
Study Phase: Not Applicable
View 2 Less Clinical Trials

95 Total Publications

Efficacy and safety of low-dose IL-2 as an add-on therapy to riluzole (MIROCALS): a phase 2b, double-blind, randomised, placebo-controlled trial.
Efficacy and safety of low-dose IL-2 as an add-on therapy to riluzole (MIROCALS): a phase 2b, double-blind, randomised, placebo-controlled trial.
Journal: Lancet (London, England)
Published: October 25, 2024

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Salachas's expertise for a condition
ConditionClose
    View All 23 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile